{
  "case_id": "MN23-39808",
  "year": 2023,
  "patient_info": {
    "age_range": "51 to 64",
    "gender": "Male"
  },
  "diagnosis": "Lupus",
  "secondary_conditions": [],
  "complications": [],
  "symptoms": [],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Weight Control",
  "treatments_requested": [
    {
      "name": "Semaglutide",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": "GLP-1 receptor agonist for weight management"
    }
  ],
  "treatments_tried_but_failed": [],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [],
  "is_denial_upheld": false,
  "issues_considered": [
    "medical_necessity"
  ],
  "other_issues": null,
  "guidelines_support": true,
  "guidelines_not_support": null,
  "guidelines_details": "Current medical literature supports the use of Wegovy in promoting weight loss with low health risks.",
  "soc_support": true,
  "soc_not_support": null,
  "soc_details": "GLP-1 receptor agonists have an established efficacy and safety profile for weight management.",
  "study_support": true,
  "study_details": [
    {
      "study_name": "GLP-1 Receptor Agonists in Weight Management",
      "study_authors": "Various researchers",
      "key_findings": "GLP-1 analogs improve glycemic control, reduce body weight, and decrease cardiovascular risk."
    }
  ],
  "key_questions": [
    "medical_necessity"
  ],
  "expedited": true,
  "rationale": "The requested medication, Wegovy, is medically necessary for the treatment of the patient's condition due to its efficacy in weight management and low associated health risks.",
  "reviewer_credentials": "Board certified in internal medicine with sub-specialty certification in endocrinology, diabetes, and metabolism."
}